Houston researches tap into GenAI for communicating genetic test results

hi, tech

Researchers at Baylor College of Medicine’s Human Genome Sequencing Center have trained an AI assistant to explain genetic test results to patients. Photo via Getty Images

Artificial intelligence in the health care setting has a lot of potential, and one Houston institution is looking into one particular use.

Researchers at Baylor College of Medicine’s Human Genome Sequencing Center have trained an AI assistant to explain genetic test results to patients. According to findings published in the Journal of the American Medical Informatics Association (JAMIA), the team has developed generative AI to understand and interpret genetic tests. They have also tested its accuracy against Open AI’s ChatGPT 3.5.

“We created a chatbot that can provide guidance on general pharmacogenomic testing, dosage implications, and the side effects of therapeutics, and address patient concerns,” explains first author Mullai Murugan in a press release. Murugan is director of software engineering and programming at the Human Genome Sequencing Center. “We see this tool as a superpowered assistant that can increase accessibility and help both physicians and patients answer questions about genetic test results.”

The initial chatbot training specifically targeted pharmacogenomic testing for statins, meaning a patient’s potential response to cholesterol-lowering drugs, as dictated by genetics.

Murugan explains why they decided to create their own chatbot in the key publication on statin pharmacogenomics was published in May 2022, four months after the training cutoff date for ChatGPT 3.5 in January 2022. Alternatively, her team’s technology uses Retrieval Augmented Generation (RAG) and was trained on the most recent guidelines.

How did the two AI assistants compare? Four experts on cardiology and pharmacogenomics rated both chatbots based on accuracy, relevancy, risk management, and language clarity, among other factors. Though the AI scored similarly on language clarity, Baylor’s chatbot scored 85 percent in accuracy and 81 percent in relevancy compared to ChatGPT’s 58 percent in accuracy and 62 percent in relevancy when asked questions from healthcare providers.

“We are working to fine-tune the chatbot to better respond to certain questions, and we want to get feedback from real patients,” Murugan says. “Based on this study, it is very clear that there is a lot of potential here.” Nonetheless, Murugan emphasized that there is much work still to be done before the program is ready for clinical applications. That includes training the chatbot to explain results in the language used by genetic counselors. Funds from the NIH’s All of Us Research Program helped to make the research possible.

From Your Site Articles
Houston-based alive5 has over 800 customers using their chatbox services — and has found a special niche in sports team's websites. Photo via alive5.com

Houston startup hopes to revolutionize the chatbot business

chatterboxes

It seems like every other webpage nowadays has a virtual assistant that pops up via a chat box. A Houston startups is hoping to ride the wave of this digital marketing initiative.

Houston-based alive5 has created a platform that allows small-to-medium-sized businesses to engage customers using Chatbot Technology, from their websites, apps, SMS text-message, and social media pages.

"What we do at alive5 is really simple," says Glenn Gutierrez, COO and co-founder of alive5. "We help your business make more conversations."

Gutierrez and his co-founder Dustin Yu started out in 2017 as Alive Chat System and they were one of the first chat systems in Texas.

"Our chat system was kind of a common system that you might see on a website that says, 'Hey, how can I help you today?" says Gutierrez. "And when you press that button, somebody on the other end sends a message and says, 'Hey, how are you doing today? How can I help you?"

After exploring how to take the company, which was initially a lifestyle product, to scale, they added new products and found new ways for their clients to have more conversations with their customers.

"We had to create as many channels as possible outside of web chat," says Gutierrez. "We talked about the live chat system, moving into SMS text message, moving into social media and interestingly enough, we started moving into business cards with QR codes where people can actually scan a QR code or text a phone number and we can automatically build a relationship with a customer at an event, in person or from a billboard.

"And that activates pretty much all the rest of the system for businesses to be able to engage a customer. So we think about ourselves as the best way to help you create more conversations, not just on your website, but pretty much anywhere you would engage a customer."

The platform enjoyed a meteoric rise in the chat space due to its participation in Capital Factory's accelerator program. From there, they were placed in another accelerator program in Philadelphia, the Comcast NBCUniversal LIFT Labs Accelerator, powered by Techstars.

"Because of the boost from the accelerator programs, we developed relationships with a lot of great organizations," says Gutierrez. "Today, we service over 800 customers, including 200 of the top college sports teams and pro teams like the NBA, NFL and NHL."

The platform's collaboration helps teams sell more tickets, especially premium seat tickets, by facilitating conversations with VIP clients and allowing fans the opportunity to go to the team's website to use the automated chat solution.

"A good example of one of those is the Jacksonville Jaguars website," says Gutierrez. "You can go there and see one of our chat boxes available to assist with inquiries or questions that you may have before, during or after a game. And our solution is built for organizations with a high volume of customer interactions to automate some of those tier one questions."

Alive5 also services customers like Royal Caribbean Cruise Line, major hotel brands and other companies in the hospitality space. They are also now collaborating with Spectra Venue Management, which manages hundreds of venues throughout North America, to pilot alive5's messaging and concierge services.

Outside of their inroads in the chat space, the platform is creating AI-powered strategies to help companies maximize their communication opportunities at personal touchpoint events such as conferences and trade shows.

"With our A.I. powered business cards, we're able to take an engagement that happens at a conference, an event or at a networking session and turn that into a prospect that's now part of a company's digital lead funnel," says Gutierrez. "What we're proposing is to give them a laser-etched metal business card with the QR code. That is better than just giving them a paper business card that they will take and may or may not call you and that's it, that's the end of the interaction.

"With the QR code, a potential contact can scan it and it will send them a demo of our product to their phone and it will give them all of a client's contact details so they can reach out to that client anytime they're ready to buy. The best part about that is that now you have something that no other system can do and you have that customer's phone number available to you at any point in time."

Moving forward, the Houston-based platform wants to do everything within its power to be one of the most successful chat companies nationwide.

"I like to think about our product like a Lego set," says Gutierrez. "It's up to you to choose what package you want. I've been in the startup space for a long time and to finally see that ecosystem starting to mature to the point that businesses are more open to digitally transforming their organizations, where they're understanding the need to take risks, to try new things, that's great for us.

"When you think about a company that can help you with your communication, I want alive5 to be the first company on their minds."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Baylor College of Medicine launches VC fund to invest in biotech startups

fresh funding

Houston’s Baylor College of Medicine just unveiled a new venture capital fund that backs early-stage biotech startups—and it’s already made its first investment.

BCM Legacy Fund I, funded by philanthropies, invested an undisclosed amount in Houston biotech startup Nemea Therapeutics. Nemea, a spinout of the Baylor College of Medicine and Germany’s Lead Discovery Center, is developing an oral drug to treat metastatic triple-negative breast cancer that no longer responds to currently available therapies.

This type of aggressive cancer spreads from the breast to other areas of the body, such as the bones, liver, lungs or brain. Roughly 38,000 to 57,000 Americans are diagnosed each year with metastatic triple-negative breast cancer. One study showed about half of patients survive past the one-year mark following diagnosis and about one-third survive two years.

“Baylor College of Medicine’s laboratories produce discoveries with the potential to change patients’ lives, and too many of them stall where academic funding ends and private investment has not yet begun,” Dr. Jakub Tolar, president, CEO and executive dean of the Baylor College of Medicine, said in a press release. “The BCM Legacy Fund fills that gap, giving our scientists a path to advance their discoveries to patients.”

The National Institutes of Health awards more than $36 billion per year for biomedical research in the U.S., Baylor said. But some biomedical discoveries “never leave the starting line because they don’t yet fit the economics of venture capital,” the college said.

“The forefront of a new model”

The BCM Legacy Fund aggregates philanthropic capital from private foundations and donor-advised funds. It then invests in startups so they can move beyond that starting line and into later-stage investment rounds. The Greater Houston Community Foundation is the fund’s philanthropic partner.

“It’s exciting to be on the forefront of a new model for philanthropic capital,” said Houston entrepreneur and investor Burton Hanson, managing partner of the fund.

“Not only do we hope to solve a real problem by advancing these therapies to the patients who need them most, but we also hope this model will inspire others in the city and beyond toward philanthropic creativity and a posture of ‘I sacrifice; we win.’”

The fund expects to invest in about 15 early-stage startups over a five-year span. Baylor declined to divulge the amount of money in the fund and the size of the investment in Nemea.

Nemea’s “world-class chemistry”

Hanson oversees the Baylor fund alongside Chicago investor Steve Lehmann, who led the University of Chicago’s Innovation Fund.

Lehmann said Nemea, the fund’s first portfolio company, “has world-class chemistry, Baylor biology, and patients with no good options. Our job is to fund the experiments that carry it to the next handoff, so that industry and later-stage investors can take it from there.”

Based at Houston’s massive Texas Medical Center, Nemea plans to start clinical trials next year in collaboration with Baylor’s Lester and Sue Smith Breast Center.

Nemea previously received $9 million from the Lead Discovery Center and a $1.6 million grant from Baylor. Last year, the startup said it was seeking $25 million to $30 million in seed and Series A funding.

Debra McCoy of Houston, a former managing director at BlackRock and former partner at Bain & Co., and Paul Thomas, co-founder and CEO of Spring-based benefits manager Luscinia Health, sit on the Baylor fund’s governing board. Dr. Paul Klotman, former president, CEO and executive dean of Baylor, is a senior strategic adviser.

How does the fund find investment targets?

The Baylor Legacy Fund relies on two tools to help unearth early-stage biotech startups:

  • High-resolution “innovation maps” of research institutions. These maps surface hidden clusters of innovation, identify rising-star researchers and tie pockets of “innovation supply” at Baylor to areas of “innovation demand” in biotech.
  • AI-enhanced due diligence. AI agents assist with due diligence of early-stage biotech startups. The fund says the platform “distills the frameworks we’ve developed over a decade of teaching and investing into a flexible … diligence environment.”

MD Anderson unveils $3.4B expansion with two new Houston cancer care facilities

major expansion

The cutting edge of cancer-fighting technology and science is getting even sharper after MD Anderson announced last week that it will open two new facilities in the Texas Medical Center within the next five years. Inspiration Tower and Prism will expand MD Anderson’s annual patient load in the TMC to 250,000 annually and will incorporate a variety of new techniques.

The $3.4 billion project will add 2 million square feet to MD Anderson's TMC footprint, bringing its total campus size to 22 million square feet by 2032. Located at the corner of Fannin Street and Holcombe Boulevard, the cancer center says the two new facilities will serve as its new "front door" to the TMC.

“Every detail of these buildings, from the technology to the treatment rooms, was designed around our patients who will receive their care in them and our employees who will work in them. The facilities will serve as a physical representation of hope for the patients and their families who will walk through the doors,” Dr. Jeffrey E. Lee, president ad interim of UT MD Anderson, said in a news release. “Inspiration Tower and Prism are the future of cancer care, and we are grateful for the longstanding support and guidance we’ve received from the UT System Board of Regents to bring these projects to life. These facilities are part of the most impactful capital expansion in UT MD Anderson’s history.”

Prism is especially exciting as it will represent fully half of the linear accelerator treatment in the TMC. Linear accelerator is a radiation treatment that uses magnetically charged fields to deliver targeted external radiation therapy, like shooting cancer with a rail gun. The treatment is safer and has fewer side effects than older radiation treatments.

In addition, Prism will contain 12 MRI machines, four CT scanners, two PET-CT units, 18 radiation vaults and seven radiation simulators. Patient comfort has also been put at a premium with multiple gardens and roof overlooks.

“Every patient we treat deserves an environment that reflects the excellence of the care they receive at UT MD Anderson,” Chris McKee, executive vice president and chief strategy officer at UT MD Anderson, added in the release. “Our new facilities will be innovative, agile, adaptable and beautiful, and they will allow us to care for more patients, more effectively – in an environment that enhances healing and well-being. We are building for our future and for every patient who will be counting on us.”

Prism is slated to open in 2030.

Inspiration Tower will have 25 floors of surgical, diagnostic, and treatment services. At 1.4 million square feet, it’s currently expected to be the largest cancer-specific treatment facility in the United States. The tower will be divided into units for specific types of cancer, making it easy to integrate the advancing research being done all over Houston.

Like Prism, Inspiration Tower is specifically designed to offer comfort and reassurance, with more garden space, terraces, and beautiful scenery to ease patient distress. It is expected to open in 2032.

Tesla will pull the plug on Cybertruck production at Texas factory in 2027

Tesla Talk

Tesla’s Cybertruck, the hulking, stainless-steel pickup that inspired devotion and derision with its science-fiction looks, will cease production next year.

CEO Elon Musk announced the model’s demise Friday, November 6, with a curt post on X, his social media site, simply noting production of the vehicle “will be winding down” around the middle of 2027 at its facility outside Austin, Texas. Musk said the move was to allow increased production of its Cybercab robotaxi.

For the Cybertruck, a pet project of Musk who insisted it was Tesla’s best product, it marks an unceremonious end to one of the auto industry’s most ballyhooed debuts.

“Few vehicles in history have generated as much attention,” said Armen Hareyan, whose Torque News site covers autos. “The Cybertruck became a cultural symbol – loved, mocked and impossible to ignore.”

The Cybertruck rolled onto the scene in a dramatic unveiling in 2019, when a Tesla designer hurled a metal ball at the vehicle to demonstrate its supposedly unbreakable glass, only to see it shatter. He repeated the stunt on another window of the truck only to shatter that one, too.

Even as some critics scoffed, Musk was steadfast.

“I just wanted to make a futuristic battle tank — something that looks like it could come out of ‘Blade Runner’ or ‘Aliens’ or something like that but was also highly functional,” he told Automotive News. He called it “a better sports car than a Porsche 911” and “a better truck than an F-150.”

It struck some as the perfect vehicular reflection of the brash, convention-busting Musk.

“A really controversial vehicle unveiled by a controversial individual into a market where none of the electric trucks have been able to really capture demand,” said Spencer Penn, a former Tesla executive who left the company before the Cybertruck’s launch and now heads software developer LightSource.

Penn remembered watching the unveiling and feeling initially revolted by the sight of the Cybertruck, calling its appearance “madness.” But the more he looked at it, the more his opinion changed. He signed up for a pre-sale reservation, though ended up not getting a Cybertruck when Musk’s promises of a price tag under $40,000 went unmet and the first trucks sold for double or more. Penn called the Cybertruck part of Tesla’s adventurous spirit that drives innovation.

“Some of these bets work and some of these bets don’t,” he said.

While the decision to end Cybertruck production may be driven by sales realities, it's also a reflection of Tesla’s shift to autonomous vehicles, on which Musk is betting the company’s future.

Musk once forecast he’d make 250,000 Cybertrucks a year. Kelley Blue Book estimated Tesla sold just 20,237 of the vehicles last year, down about half from the year prior. Sales through the end of September this year were down another 28%, according to Kelley Blue Book.

If the imposing, sharp-angled, dystopian appearance of the Cybertruck weren’t enough to turn many potential buyers away, Musk did so himself by allying with a panoply of right-wing figures, most notably U.S. President Donald Trump. He alienated some customers as his image morphed from eccentric innovator to polarizing force trading his billions for political influence.

Once-passionate Tesla drivers rushed to sell off their cars, or slapped stickers on the bumper declaring, “I bought this before Elon went crazy.” Organizers staged demonstrations outside Tesla showrooms and urged investors to dump shares of the company’s stock. Anger spilled into violence, with Molotov cocktails hurled at Tesla vehicles, charging stations set ablaze, and dealerships covered in graffiti.

Lovers of the Cybertruck became targets, too, subjected to shouts of “Nazi!” and extended middle fingers.

Ross Blankenship is one of them. When he first laid eyes on the Cybertruck, he felt transported to a world from his childhood, when he would play “Halo,” the sci-fi video game. He had to have it.

“I had that sort of child in me wanting to be part of something cool that would change the future of automotive,” Blankenship said in a call from his Cybertruck as he drove through Sunnyside, Colorado. Even as Blankenship found he agreed with Musk on politics, he hated seeing a vehicle he loved turned into a political symbol. “I never bought it for any other reason than the fascination with the future technology of trucks … so that was a little heartbreaking.”

He would buy another Cybertruck again in a heartbeat, calling its end “a sad moment.”

View All Listings